Rimes-Stigare Claire, Frumento Paolo, Bottai Matteo, Mårtensson Johan, Martling Claes-Roland, Walther Sten M, Karlström Göran, Bell Max
Department of Anaesthesia, Surgical Services and Intensive Care (ANOPIVA) F2, Karolinska University Hospital, Solna, 171 76, Stockholm, Sweden.
Section of Anaesthesia and Intensive Care Medicine, Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden.
Crit Care. 2015 May 6;19(1):221. doi: 10.1186/s13054-015-0920-y.
Acute Kidney Injury (AKI) is common in critical ill populations and its association with high short-term mortality is well established. However, long-term risks of death and renal dysfunction are poorly understood and few studies exclude patients with pre-existing renal disease, meaning outcome for de novo AKI has been difficult to elicit. We aimed to compare the long-term risk of Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and mortality in critically ill patients with and without severe de novo AKI.
This cohort study was conducted between 2005 and 2011 in Swedish intensive care units (ICU). Data from 130134 adult patients listed on the Swedish intensive care register-database was linked with other national registries. Patients with pre-existing CKD (4192) and ESRD (1389) were excluded, as were cases (26771) with incomplete data. Patients were classified according to AKI exposure during ICU admission. Outcome in the de novo AKI group was compared to the non-exposed (no-AKI) intensive care control group. Primary outcome was all-cause mortality. Follow-up ranged from one to seven years (median 2.1 years). Secondary outcomes were incidence of CKD and ESRD and median follow-up was 1.3 years.
Of 97 782 patients, 5273 (5.4%) had de novo AKI. These patients had significantly higher crude mortality at one (48.4% vs. 24.6%) and five years (61.8% vs. 39.1%) compared to the control group. The first 30% of deaths in AKI patients occurred within 11 days of ICU admission whilst the 30-centile in the no-AKI group died by 748 days. CKD was significantly more common in AKI survivors at one year (6.0% vs. 0.44%) than in no-AKI group (adjusted incidence rate ratio (IRR) 7.6). AKI patients also had significantly higher rates of ESRD at one (2.0% vs. 0.08%) and at five years (3.9% vs. 0.3%) than those in the comparison group (adjusted IRR 22.5).
This large cohort study demonstrated that de novo AKI is associated with increased short and long-term risk of death. AKI is independently associated with increased risk of CKD and ESRD as compared to an ICU control population. Severe de novo AKI survivors should be routinely followed-up and their renal function monitored.
急性肾损伤(AKI)在危重症人群中很常见,并且其与高短期死亡率之间的关联已得到充分证实。然而,人们对其长期死亡风险和肾功能障碍了解甚少,而且很少有研究排除已有肾脏疾病的患者,这意味着新发AKI的预后一直难以确定。我们旨在比较发生和未发生严重新发AKI的危重症患者发生慢性肾脏病(CKD)、终末期肾病(ESRD)和死亡的长期风险。
这项队列研究于2005年至2011年在瑞典重症监护病房(ICU)进行。瑞典重症监护登记数据库中列出的130134名成年患者的数据与其他国家登记处的数据相关联。排除已有CKD(4192例)和ESRD(1389例)的患者,以及数据不完整的病例(26771例)。根据ICU住院期间的AKI暴露情况对患者进行分类。将新发AKI组的预后与未暴露(无AKI)的重症监护对照组进行比较。主要结局是全因死亡率。随访时间为1至7年(中位时间2.1年)。次要结局是CKD和ESRD的发生率,中位随访时间为1.3年。
在97782名患者中,5273名(5.4%)发生了新发AKI。与对照组相比,这些患者在1年(48.4%对24.6%)和5年(61.8%对39.1%)时的粗死亡率显著更高。AKI患者中前30%的死亡发生在ICU入院后的11天内,而无AKI组的第30百分位数患者在748天时死亡。AKI幸存者在1年时CKD的发生率(6.0%对0.44%)显著高于无AKI组(调整后的发病率比(IRR)为7.6)。AKI患者在1年(2.0%对0.08%)和5年(3.9%对0.3%)时ESRD的发生率也显著高于对照组(调整后的IRR为22.5)。
这项大型队列研究表明,新发AKI与短期和长期死亡风险增加相关。与ICU对照人群相比,AKI与CKD和ESRD风险增加独立相关。严重新发AKI的幸存者应进行常规随访并监测其肾功能。